loading page

Population Pharmacokinetics of Oxcarbazepine: A Systematic Review
  • +4
  • Yue-ting Chen,
  • chenyu wang,
  • Yi-wei Yin,
  • Ziran Li,
  • Wei-wei Lin,
  • Min Zhu,
  • Zheng Jiao
Yue-ting Chen
Shanghai Jiao Tong University Affiliated Chest Hospital

Corresponding Author:3319091390@stu.cpu.edu.cn

Author Profile
chenyu wang
Author Profile
Yi-wei Yin
Shanghai Jiao Tong University Affiliated Chest Hospital
Author Profile
Ziran Li
Huashan Hospital Fudan University
Author Profile
Wei-wei Lin
Author Profile
Min Zhu
Shanghai Jiao Tong University Affiliated Chest Hospital
Author Profile
Zheng Jiao
Shanghai Jiao Tong University Affiliated Chest Hospital
Author Profile

Abstract

Aim This is the first review to summarize the population pharmacokinetic studies of oxcarbazepine and explored the significant covariates that may have an impact on the dosage regimen and clinical use of oxcarbazepine. Methods PubMed and Embase databases were searched before 31 October 2020, and references of all selected studies were further screened to identify the pertinent population pharmacokinetic studies of oxcarbazepine. Relevant information about the identified population pharmacokinetic studies was summarised, and the quality of the reports was evaluated. Moreover, studies among infant, children, and adult patients were compared. Results Twelve studies were included: seven studies enrolled paediatric patients only; two enrolled both paediatric and adult patients; and two enrolled adult patients only. The apparent clearance per weight for children (median: 0.0505 L/h/kg, range: 0.016-0.084) and infants (0.078 L/h/kg) were higher than that for adults (median: 0.036 L/h/kg, range: 0.029-0.06). Furthermore, children had a larger variation on clearance compared to adults. Weight, co-administration with enzyme-inducing antiepileptic drugs, and renal function were found to significantly affect clearance of 10-hydroxycarbazepine. Conclusion The oxcarbazepine dose regimen was dependent on weight, co-administration with enzyme-inducing medications, and renal function. Further study is essential to explore the pharmacodynamics in epilepsy patients and pharmacokinetics of oxcarbazepine in infants.
03 Jul 2021Published in Expert Review of Clinical Pharmacology volume 14 issue 7 on pages 853-864. 10.1080/17512433.2021.1917377